



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 75151

**Title:** Tumor-feeding artery diameter reduction is associated with improved short-term effect of hepatic arterial infusion chemotherapy plus lenvatinib treatment

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 01221925

**Position:** Editorial Board

**Academic degree:** AGAF, FACS, FICS, MD, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** Greece

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-01-22

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-01-25 15:32

**Reviewer performed review:** 2022-01-25 15:36

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
-------------------------------------	---

### **SPECIFIC COMMENTS TO AUTHORS**

THIS is a very interesting paper providing insights into the challenging management of unresectable HCC. Could the authors discuss the following: 1) COuld the authors compare their approach to other ones including the use of other immune inhibitors or combination of them (ie HIMALAYAS pilot study) 2) Also could the author discuss the possibility of downstaging with this combination



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 75151

**Title:** Tumor-feeding artery diameter reduction is associated with improved short-term effect of hepatic arterial infusion chemotherapy plus lenvatinib treatment

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05342613

**Position:** Editorial Board

**Academic degree:** FACS

**Professional title:** Professor

**Reviewer's Country/Territory:** Turkey

**Author's Country/Territory:** China

**Manuscript submission date:** 2022-01-22

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-01-24 10:31

**Reviewer performed review:** 2022-01-28 08:34

**Review time:** 3 Days and 22 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No
-------------------------------------	---

**SPECIFIC COMMENTS TO AUTHORS**

1 Title. OK 2 Abstract.OK 3 Key words. YES 4 Background. YES 5 Methods. In order to evaluate the data obtained in the HAIC+Lenvatinib combination correctly, the data to be obtained will be much more meaningful if they are compared with the data of the patient group who received only HAIC treatment (as a control group). 6 Results. In order to evaluate the data obtained in the HAIC+Lenvatinib combination correctly, the data to be obtained will be much more meaningful if they are compared with the data of the patient group who received only HAIC treatment (as a control group). 7 Discussion. In the discussion section, it was written that studies with Sorafenib also reported narrowing in tumor-related arterial diameters. It is not enough to just write this as a discussion. In order to evaluate the data obtained in the HAIC+Lenvatinib combination correctly, the data to be obtained will be much more meaningful if they are compared with the data of the patient group who received only HAIC treatment (as a control group). 8 Illustrations and tables. 9 Biostatistics. OK 10 Units. YES 11 References.OK 12 Quality of manuscript organization and presentation. Well written and documented, but needs more data for HAIC and discussion 13 Research methods and reporting. YES 14 Ethics statements. OK